Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
Boundless Bio (Nasdaq: BOLD) has appointed Robert ('Bob') Doebele, M.D., Ph.D., as Chief Medical Officer. Dr. Doebele brings over 15 years of oncology drug development experience to the clinical-stage oncology company, which focuses on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers.
Dr. Doebele was previously co-founder and Chief Scientific and Medical Officer at Rain Oncology (acquired by Pathos AI), where he led development of precision oncology therapies. His notable achievements include leading research at the University of Colorado that pioneered the TRK inhibitor field, contributing to the approval of Vitrakvi® and Rozlytrek®.
At Boundless Bio, Dr. Doebele will oversee the advancement of the BBI-355 Phase 1/2 POTENTIATE trial and the selection of a development candidate for the company's Kinesin program.
Boundless Bio (Nasdaq: BOLD) ha nominato Robert ('Bob') Doebele, M.D., Ph.D., come Chief Medical Officer. Il Dr. Doebele porta oltre 15 anni di esperienza nello sviluppo di farmaci oncologici nella società oncologica in fase clinica, che si concentra sulla biologia del DNA extracromosomico (ecDNA) per il trattamento dei tumori amplificati da oncogeni.
Il Dr. Doebele è stato precedentemente cofondatore e Chief Scientific e Medical Officer di Rain Oncology (acquisita da Pathos AI), dove ha guidato lo sviluppo di terapie di oncologia di precisione. Tra i suoi risultati notevoli c'è la ricerca condotta presso l'Università del Colorado che ha aperto la strada nel campo degli inibitori TRK, contribuendo all'approvazione di Vitrakvi® e Rozlytrek®.
Presso Boundless Bio, il Dr. Doebele sovrintenderà all'avanzamento dello studio BBI-355 di Fase 1/2 POTENTIATE e alla selezione di un candidato per lo sviluppo del programma Kinesin della società.
Boundless Bio (Nasdaq: BOLD) ha nombrado a Robert ('Bob') Doebele, M.D., Ph.D., como Director Médico. El Dr. Doebele aporta más de 15 años de experiencia en el desarrollo de fármacos oncológicos a la compañía oncológica en etapa clínica, que se centra en la biología del ADN extracromosómico (ecDNA) para tratar cánceres amplificados por oncogenes.
El Dr. Doebele fue anteriormente cofundador y Director Científico y Médico en Rain Oncology (adquirida por Pathos AI), donde lideró el desarrollo de terapias de oncología de precisión. Sus logros notables incluyen la dirección de investigaciones en la Universidad de Colorado que pioneras en el campo de los inhibidores de TRK, contribuyendo a la aprobación de Vitrakvi® y Rozlytrek®.
En Boundless Bio, el Dr. Doebele supervisará el avance del ensayo BBI-355 de Fase 1/2 POTENTIATE y la selección de un candidato para el programa Kinesin de la compañía.
Boundless Bio (Nasdaq: BOLD)는 로버트('밥') 도벨 박사(M.D., Ph.D.)를 Chief Medical Officer로 임명했습니다. 도벨 박사는 종양 유전자 증폭 암 치료를 위한 엑트로모좀 DNA(ecDNA) 생물학에 중점을 둔 임상 단계 종양학 회사에 15년 이상의 항암제 개발 경험을 가져왔습니다.
도벨 박사는 이전에 레인 온콜로지(Rain Oncology)에서 공동 창립자 및 Chief Scientific and Medical Officer로 재직하며 정밀 종양학 치료 개발을 이끌었습니다. 그의 주요 성과로는 콜로라도 대학교에서 TRK 억제제 분야의 연구를 선도하여 Vitrakvi® 및 Rozlytrek®의 승인을 이끄는 것입니다.
Boundless Bio에서 도벨 박사는 BBI-355 1/2상 POTENTIATE 임상시험을 진행하고 회사의 키네신 프로그램을 위한 개발 후보 선정을 총괄할 것입니다.
Boundless Bio (Nasdaq: BOLD) a nommé Robert ('Bob') Doebele, M.D., Ph.D., au poste de directeur médical. Le Dr Doebele apporte plus de 15 ans d'expérience dans le développement de médicaments oncologiques à l'entreprise d'oncologie en phase clinique, qui se concentre sur la biologie de l'ADN extracromosomique (ecDNA) pour traiter les cancers amplifiés par des oncogènes.
Le Dr Doebele était auparavant cofondateur et directeur scientifique et médical chez Rain Oncology (acquis par Pathos AI), où il a dirigé le développement de thérapies d'oncologie de précision. Parmi ses réalisations notables figure la direction de recherches à l'université du Colorado qui a ouvert la voie dans le domaine des inhibiteurs de TRK, contribuant à l'approbation de Vitrakvi® et Rozlytrek®.
Chez Boundless Bio, le Dr Doebele supervisera l'avancement de l'essai BBI-355 Phase 1/2 POTENTIATE et la sélection d'un candidat à développement pour le programme Kinesin de l'entreprise.
Boundless Bio (Nasdaq: BOLD) hat Robert ('Bob') Doebele, M.D., Ph.D., zum Chief Medical Officer ernannt. Dr. Doebele bringt über 15 Jahre Erfahrung in der Entwicklung von Onkologika in das klinische Onkologieunternehmen ein, das sich auf die Biologie von extrachromosomalem DNA (ecDNA) zur Behandlung von amplifizierten Onkogen-Krebsarten konzentriert.
Dr. Doebele war zuvor Mitbegründer und Chief Scientific and Medical Officer bei Rain Oncology (erworben von Pathos AI), wo er die Entwicklung von Präzisionsonkologie-Therapien leitete. Zu seinen bemerkenswerten Leistungen gehört die Forschung an der Universität Colorado, die das Feld der TRK-Inhibitoren mitbegründete und zur Zulassung von Vitrakvi® und Rozlytrek® beitrug.
Bei Boundless Bio wird Dr. Doebele die Fortschritte der BBI-355 Phase 1/2 POTENTIATE-Studie und die Auswahl eines Entwicklungskandidaten für das Unternehmensprogramm Kinesin überwachen.
- Appointment of experienced CMO with 15+ years in oncology drug development
- New CMO has successful track record in precision oncology drug development
- CMO brings expertise in biomarker-driven clinical trials and drug approvals
- None.
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers -
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer.
“We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Bob has been a driving force behind precision oncology drug development throughout his career. His leadership in clinical development will be instrumental in advancing our ecDTx programs and, most importantly, in delivering novel treatment options to patients with oncogene amplified cancers.”
Dr. Doebele was the co-founder of Rain Oncology, Inc., (acquired by Pathos AI), a precision oncology company, where he served as Chief Scientific and Medical Officer, directing the research and development of innovative therapies targeting oncogenic drivers in tumor-agnostic, biomarker-driven trials. Specifically, he led the clinical development plans for milademetan, a small molecule MDM2 inhibitor, Phase 2 planning for tarloxotinib, a hypoxia-activated pan-HER kinase inhibitor, and the development of a preclinical program focused on inducing synthetic lethality by inhibiting RAD52. Dr. Doebele previously led the research and clinical trials at the University of Colorado that launched the TRK inhibitor field by demonstrating that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of Vitrakvi® (larotrectinib) and Rozlytrek® (entrectinib). He also served as the director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and co-founded and co-directed the University of Colorado Molecular Tumor Board. Dr. Doebele received his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine and an A.B. in Molecular Biology from Princeton University.
“I am thrilled to join Boundless Bio, a company focused on interrogating novel biology to develop treatments for patients with oncogene amplified cancers,” said Dr. Doebele. “In my career as a biotech executive, scientist, and clinician, I have witnessed the potential of precision oncology to deliver meaningful outcomes for patients. Despite these advancements, there are very few treatments that effectively treat patients with oncogene amplifications, and I look forward to joining Boundless’ mission to develop life-improving therapies for these patients.”
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than
Forward-Looking Statements
Boundless Bio cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include but are not limited to: our ability to advance our ecDTx programs, and deliver novel, life-improving treatment options to patients. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: we are early in our development efforts and our approach to discover and develop ecDTx directed against ecDNA in oncogene amplified cancers is novel and unproven; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Investors
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Media
Carly Scaduto
carly@carlyscadutoconsulting.com
FAQ
What is the significance of Dr. Doebele's appointment as CMO for Boundless Bio (BOLD)?
What are Dr. Doebele's major achievements before joining Boundless Bio (BOLD)?
What clinical trials is Boundless Bio (BOLD) currently conducting?
What is Boundless Bio's (BOLD) main therapeutic focus?
